BACKGROUNDResearch and Commercialization Agreement • January 26th, 2000 • Medarex Inc • Biological products, (no disgnostic substances) • California
Contract Type FiledJanuary 26th, 2000 Company Industry Jurisdiction
RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • September 22nd, 2004 • Celldex Therapeutics Inc • Biological products, (no disgnostic substances) • New Jersey
Contract Type FiledSeptember 22nd, 2004 Company Industry JurisdictionThis Research and Commercialization Agreement (the “Agreement”), effective as of April 6, 2004 (the “Effective Date”), is entered by and between Medarex, Inc., a New Jersey corporation, with a principal place of business at 707 State Road, Princeton, New Jersey 08540, GenPharm International, Inc., a wholly owned subsidiary of Medarex, Inc., (collectively, “Medarex”), and Celldex Therapeutics, Inc., a Delaware corporation, with a principal place of business at 519 Route 173 W, Bloomsbury, New Jersey 08804 (“Celldex”).
RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • January 18th, 2008 • Avant Immunotherapeutics Inc • In vitro & in vivo diagnostic substances • New Jersey
Contract Type FiledJanuary 18th, 2008 Company Industry JurisdictionTHIS RESEARCH AND COMMERCIALIZATION AGREEMENT (the “Agreement”), effective as of April 6, 2004 (the “Effective Date”), is entered by and between MEDAREX, INC., a New Jersey corporation, with a principal place of business at 707 State Road, Princeton, New Jersey 08540, GENPHARM INTERNATIONAL, INC., a wholly owned subsidiary of Medarex, Inc., (collectively, “Medarex”), and CELLDEX THERAPEUTICS, INC., a Delaware corporation, with a principal place of business at 519 Route 173 W, Bloomsbury, New Jersey 08804 (“Celldex”).
RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • August 8th, 2014 • Fibrogen Inc • Pharmaceutical preparations • California
Contract Type FiledAugust 8th, 2014 Company Industry Jurisdiction
AMENDMENT NO. 1 TO RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • June 11th, 2014 • Fibrogen Inc • Pharmaceutical preparations
Contract Type FiledJune 11th, 2014 Company IndustryTHIS AMENDMENT No. 1 TO RESEARCH AND COMMERCIALIZATION AGREEMENT (“Amendment”) is made and entered into effective as of June 30, 2001 (the “Amendment Date”) by and between MEDAREX, INC., 707 State Road, Suite 206, Princeton, NJ 08540, GENPHARM INTERNATIONAL INC., a wholly-owned subsidiary of Medarex, Inc. (together, “Medarex”), and FIBROGEN, INC., a Delaware corporation, 225 Gateway Boulevard, South San Francisco, California 94080 and FIBROPHARMA, INC., a wholly-owned subsidiary of Fibrogen, Inc. (collectively, “FibroGen”). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement (as defined below).
AMENDMENT NO. 2 TO RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • October 1st, 2014 • Fibrogen Inc • Pharmaceutical preparations
Contract Type FiledOctober 1st, 2014 Company IndustryTHIS AMENDMENT NO. 2 TO RESEARCH AND COMMERCIALIZATION AGREEMENT (“Amendment”) is made and entered into effective as of January 28, 2002 (the “Amendment Date”) by and between MEDAREX, INC., 707 State Road, Suite 206, Princeton, NJ 08540, GENPHARM INTERNATIONAL INC., a wholly-owned subsidiary of Medarex, Inc. (together, “Medarex”), and FibroGen, Inc., a Delaware corporation, 225 Gateway Boulevard, South San Francisco, California 94080 and FIBROPHARMA, INC., a wholly-owned subsidiary of FIBROGEN, INC. (collectively, “FibroGen”). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement (as defined below).
AMENDMENT NO. 2 TO RESEARCH AND COMMERCIALIZATION AGREEMENTResearch and Commercialization Agreement • November 5th, 2020 • Fibrogen Inc • Pharmaceutical preparations
Contract Type FiledNovember 5th, 2020 Company IndustryThis Amendment No. 2 to research and commercialization Agreement ("Amendment") is made and entered into effective as of January 28, 2002 (the "Amendment Date") by and between Medarex, Inc., 707 State Road, Suite 206, Princeton, NJ 08540, GenPharm International Inc., a wholly-owned subsidiary of Medarex, Inc. (together, "Medarex"), and FibroGen, Inc., a Delaware corporation, 225 Gateway Boulevard, South San Francisco, California 94080 and FibroPharma, Inc., a wholly-owned subsidiary of FibroGen, Inc. (collectively, "FibroGen"). Capitalized terms used in this Amendment that are not otherwise defined herein shall have the same meanings as such terms are defined in the Agreement (as defined below).